MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, today announced that it is retracting and replacing its previously issued press release dated February 9, 2026 regarding the Company’s fiscal third quarter 2026 conference call. This press release supersedes in it ...

Core Insights - PetVivo Animal Health, Inc. has received formal acknowledgment from Health Canada for its product Spryng® with OsteoCushion® Technology as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy [1][2][3] Company Overview - PetVivo Holdings, Inc. operates as an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, leveraging human therapies for animal treatment in a capital-efficient manner [6][7] - The company has a robust pipeline of products, including Spryng® and PrecisePRP®, protected by twelve patents and six trade secrets [7] Product Details - Spryng is an intra-articular injectable device designed to support joint health and manage lameness and other joint-related issues in animals [2][4] - The product is currently available in the United States and through select international distribution partners, with plans for commercial availability in Canada anticipated in the second quarter of 2026 [4][3] Regulatory Milestone - The acknowledgment from Health Canada serves as an important endorsement of the company's scientific and regulatory strategy, reflecting its commitment to providing innovative solutions for animal health [3][4] - Despite the regulatory acknowledgment, Spryng is not expected to be immediately available in Canada due to ongoing infrastructure development and operational requirements [3]